<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - VALACICLOVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>VALACICLOVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes zoster infection, treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 g 3 times a day for 7 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes zoster infection, treatment in immunocompromised patients</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 g 3 times a day for at least 7 days and continued for 2 days after crusting of lesions.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex, treatment of first infective episode</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 mg twice daily for 5 days (longer if new lesions appear during treatment or healing is incomplete).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex infections treatment of first episode in immunocompromised or HIV-positive patients</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 g twice daily for 10 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex, treatment of recurrent infections</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 mg twice daily for 3&#8211;5 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of recurrent herpes simplex infections in immunocompromised or HIV-positive patients</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 g twice daily for 5&#8211;10 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes labialis treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2 g, then 2 g after 12 hours.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 2 g, then 2 g after 12 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex, suppression of infections</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 mg daily in 1&#8211;2 divided doses, therapy to be interrupted every 6&#8211;12 months to reassess recurrence frequency&#8212;consider restarting after two or more recurrences.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex, suppression of infections in immunocompromised or HIV-positive patients</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 mg twice daily, therapy to be interrupted every 6&#8211;12 months to reassess recurrence frequency&#8212;consider restarting after two or more recurrences.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Genital herpes, reduction of transmission (administered on expert advice)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 mg daily, to be taken by the infected partner.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of cytomegalovirus disease following solid organ transplantation</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2 g 4 times a day usually for 90 days, preferably starting within 72 hours of transplantation.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful&#8212;manufacturers advise use only when potential benefit outweighs risk.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">In adults</h3>
              <p>Manufacturer advises caution with high doses used for herpes labialis and prevention of cytomegalovirus disease&#8212;no information available.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">In children</h3>
              <p>Manufacturer advises caution with high doses used for preventing cytomegalovirus disease&#8212;no information available in children.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>For <i>herpes zoster</i>, 1&#8239;g every 12 hours if eGFR 30&#8211;50&#8239;mL/ minute/1.73&#8239;m<sup>2</sup> (1&#8239;g every 24 hours if eGFR 10&#8211; 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 500&#8239;mg every 24 hours if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>).</p><p>For <i>treatment of herpes simplex</i>, 500&#8239;mg (1&#8239;g in immunocompromised or HIV-positive patients) every 24 hours if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>For <i>treatment of herpes labialis</i>, if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, initially 1&#8239;g, then 1&#8239;g 12 hours after initial dose (if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, initially 500&#8239;mg, then 500&#8239;mg 12 hours after initial dose; if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, 500&#8239;mg as a single dose).</p><p>For <i>suppression of herpes simplex</i>, 250&#8239;mg (500&#8239;mg in immunocompromised or HIV-positive patients) every 24 hours if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>For <i>reduction of genital herpes transmission</i>, 250&#8239;mg every 24 hours if eGFR less than 15&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>Reduce dose according to eGFR for <i>cytomegalovirus prophylaxis</i> following solid organ transplantation (consult product literature).</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>For <i>herpes zoster</i>, 1&#8239;g every 12 hours if estimated glomerular filtration rate 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (1&#8239;g every 24 hours if estimated glomerular filtration rate 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 500&#8239;mg every 24 hours if estimated glomerular filtration rate less than 10&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>). </p><p>For <i>treatment of herpes simplex</i>, 500&#8239;mg (1&#8239;g in immunocompromised or HIV-positive children) every 24 hours if estimated glomerular filtration rate less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>. </p><p>For <i>treatment of herpes labialis</i>, if estimated glomerular filtration rate 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, initially 1&#8239;g, then 1&#8239;g 12 hours after initial dose (if estimated glomerular filtration rate 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, initially 500&#8239;mg, then 500&#8239;mg 12 hours after initial dose; if estimated glomerular filtration rate less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, 500&#8239;mg as a single dose). </p><p>For <i>suppression of herpes simplex</i>, 250&#8239;mg (500&#8239;mg in immunocompromised or HIV-positive children) every 24 hours if estimated glomerular filtration rate less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>Reduce dose according to estimated glomerular filtration rate for <i>cytomegalovirus prophylaxis</i> following solid organ transplantation (consult product literature).</p>
            </section>
        
            <section class="generalInformation">
              <p>Maintain adequate hydration.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>veryRare:</strong> Acute renal failure, anaemia, ataxia, confusion, convulsions, dizziness, drowsiness, dysarthria, dyspnoea, hallucinations, hepatitis, jaundice, leucopenia, neurological reactions, thrombocytopenia,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal pain, diarrhoea, fatigue, headache, nausea, photosensitivity, pruritus, rash, urticaria, vomiting,
              </p>
        
        
            <section class="advice">
                <h3>Neurological reactions</h3>
              <p>Neurological reactions (including dizziness, confusion, hallucinations, convulsions, ataxia, dysarthria, and drowsiness) more frequent with higher doses.</p>
            </section>
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>:</strong>
            Elderly (risk of neurological reactions) in adults
          </li>
          <li>
            maintain adequate hydration (especially with high doses)
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for treatment of herpes zoster in children.</p><p>Not licensed for treatment or suppression of herpes simplex infection in immunocompromised or HIV-positive children.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Valaciclovir is a pro-drug of aciclovir.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of VALACICLOVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,

            <div id="PHP76757"><a href="../medicinalForm/PHP76757.html" data-target="#PHP76757" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
